Quick Answer
TREACE MEDICAL CONCEPTS, INC. reported Long Term Debt of $55.58 million for the year ending 2025.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +4.3% in Long Term Debt from 2024 to 2025.
- This data is from TREACE MEDICAL CONCEPTS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $29.23 million | Q2 2021: $29.28 million | Q3 2021: $29.32 million | Q1 2022: $29.41 million | Q2 2022: $52.56 million | Q3 2022: $52.64 million | Q1 2023: $52.79 million | Q2 2023: $52.86 million | Q3 2023: $52.93 million | Q1 2024: $53.08 million | Q2 2024: $53.16 million | Q3 2024: $53.23 million | Q1 2025: $53.38 million | Q2 2025: $53.45 million | Q3 2025: $53.53 million.
- Over the full 6 years of available data (2020 to 2025), TREACE MEDICAL CONCEPTS, INC.'s Long Term Debt has grown by 90.4%.
- Historical annual values: Fiscal year 2025: $55.58 million | Fiscal year 2024: $53.31 million | Fiscal year 2023: $53.01 million | Fiscal year 2022: $52.71 million | Fiscal year 2021: $29.37 million | Fiscal year 2020: $29.19 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: